6. SAB Biotherapeutics Inc. (NASDAQ:SABS)
SAB Biotherapeutics Inc. (NASDAQ: SABS) takes the sixth position among the best stocks under $10 that could triple, with shares recently trading at approximately $3.54 after declining 3.41%. The clinical-stage biotechnology company is developing human polyclonal immunotherapies, with its leading program focused on changing the course of type 1 diabetes.
On July 7, SAB Biotherapeutics Inc. (NASDAQ: SABS) and Breakthrough T1D announced that the diabetes research and advocacy organization had awarded a research grant to Michael J. Haller, M.D., Chief of Pediatric Endocrinology and a professor at the University of Florida.
The funding will support PRISE-hATG, a clinical assessment involving SAB-142 in patients with Stage 3 type 1 diabetes. The study will include individuals who are between approximately 100 days and two years from their initial diagnosis.
The trial is designed to determine whether SAB-142 can preserve endogenous C-peptide and regulate immune responses. C-peptide is commonly used as an indicator of how much insulin a person’s pancreas is still producing. Preserving C-peptide levels could suggest that a therapy is helping protect the remaining insulin-producing beta cells.
This is central to the scientific thesis behind SAB-142. Type 1 diabetes is an autoimmune disease in which the immune system attacks and destroys pancreatic beta cells. By the time many patients are diagnosed, a substantial portion of those cells has already been lost. However, some residual beta-cell function can remain during the period following diagnosis.
The PRISE-hATG assessment will focus on individuals who still have residual beta-cell activity after the first 100 days following a Stage 3 diagnosis. Researchers want to determine whether SAB-142 can help preserve that remaining function while modifying the harmful immune response.
A treatment capable of slowing or altering the progression of type 1 diabetes would represent an important medical advance. Current management generally requires lifelong insulin replacement, blood-glucose monitoring, dietary planning, and constant attention to the risk of high or low blood sugar. Even with modern insulin-delivery systems, the burden on patients and families remains substantial.
On June 24, Barclays analyst Eliana Merle initiated coverage of SAB Biotherapeutics Inc. (NASDAQ: SABS) with an Overweight rating and a $13 price target. Based on the referenced share price, the target represented potential upside of more than 240%.
Merle identified SAB-142 as a potentially valuable disease-modifying treatment for type 1 diabetes. The distinction between disease management and disease modification is crucial. Insulin helps patients control blood-glucose levels, but a disease-modifying immunotherapy could potentially preserve the body’s remaining insulin-producing capacity and address part of the autoimmune process itself.
The analyst expects Phase 2b data for SAB-142 to serve as a major catalyst for SAB Biotherapeutics Inc. (NASDAQ: SABS). Results are anticipated during the second half of 2027, making this a longer-term clinical story rather than a stock built entirely around an immediate catalyst.
The substantial analyst-implied upside reflects the potential value of success in type 1 diabetes. The disease affects a large global patient population and creates lifelong healthcare costs. A treatment that preserves beta-cell function, reduces insulin dependence, improves glucose control, or lowers the risk of complications could attract strong interest from patients, physicians, insurers, and larger pharmaceutical companies.
However, investors must be realistic about the uncertainty involved. Immunotherapies can be difficult to develop because the immune system is highly complex. A treatment must be powerful enough to alter the autoimmune response without producing unacceptable side effects, excessive immune suppression, or other safety problems.
Clinical researchers must also determine the correct patient population, timing, dosage, and treatment duration. A therapy may perform differently in newly diagnosed patients than in those who have lived with type 1 diabetes for several years. The presence or absence of residual beta-cell activity could also affect outcomes.
SAB Biotherapeutics Inc. (NASDAQ: SABS) is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies. Its primary product candidate, SAB-142, is being evaluated in Phase 2b clinical development for autoimmune type 1 diabetes.
The company’s platform is based on producing fully human polyclonal antibodies. Unlike monoclonal antibodies, which generally target a single antigen or pathway, polyclonal antibodies can recognize multiple targets. This broader activity may offer therapeutic advantages in diseases involving complex immune mechanisms, although it can also create additional challenges involving manufacturing, consistency, dosing, and regulatory review.
For SAB Biotherapeutics Inc. (NASDAQ: SABS), the investment case rests on whether this platform can produce a safe and effective treatment capable of changing the progression of type 1 diabetes. The support from Breakthrough T1D adds scientific and advocacy credibility to the program, while the Barclays coverage gives the company greater visibility among institutional investors.
Still, the timeline requires patience. With an important Phase 2b catalyst expected in the second half of 2027, shareholders may face clinical updates, financing events, market volatility, and possible dilution before receiving the most consequential data.
For investors seeking diabetes stocks, immunotherapy stocks, biotechnology stocks under $5, and clinical-stage companies with multibagger potential, SAB Biotherapeutics Inc. (NASDAQ: SABS) stands out because of its ambitious goal. If SAB-142 demonstrates that it can preserve beta-cell function and meaningfully alter the course of type 1 diabetes, the company’s current valuation could change dramatically.
The opposite is also true. A disappointing trial would undermine the central investment thesis and could place severe pressure on the stock. SAB Biotherapeutics Inc. (NASDAQ: SABS) therefore belongs in the high-risk, high-upside category of stocks under $10 that could triple—but only if its science ultimately delivers.
YOU MUST READ THIS: 10 Robotics Stocks to Buy Now as Amazon (AMZN) Hits 1M Robots
Click here to continue reading and checkout the 5 Stocks Under $10 Analysts Believe Could Soar 200%.
Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.
